Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: RAPAMUNE

« Back to Dashboard

Summary for Tradename: RAPAMUNE

Patents:3
Applicants:1
NDAs:2
Suppliers: see list3

Pharmacology for Tradename: RAPAMUNE

Clinical Trials for: RAPAMUNE

RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
Status: Completed Condition: Metastatic Renal Cell Carcinoma

Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)
Status: Active, not recruiting Condition: Tuberous Sclerosis Complex

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus in Healthy Subjects
Status: Completed Condition: Healthy Subjects; Pharmacokinetics of Isavuconazole; Pharmacokinetics of Sirolimus

Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma
Status: Terminated Condition: Bladder Cancer

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
Status: Recruiting Condition: Advanced Cancer

Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer
Status: Recruiting Condition: Metastatic Breast Cancer

STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma
Status: Recruiting Condition: Diffuse Large B-Cell Lymphoma

A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
Status: Completed Condition: Advanced Solid Tumors

Sirolimus for Autoimmune Disease of Blood Cells
Status: Recruiting Condition: Autoimmune Pancytopenia; Autoimmune Lymphoproliferative Syndrome (ALPS); Evans Syndrome; Idiopathic Thrombocytopenic Purpura; Anemia, Hemolytic, Autoimmune; Autoimmune Neutropenia; Lupus Erythematosus, Systemic; Inflammatory Bowel Disease; Rheumatoid Arthritis

Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC
Status: Terminated Condition: Non-Small Cell Lung Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110Feb 23, 2004DISCNNo5,989,591*PED<disabled>Y<disabled>
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110Aug 22, 2002RXYes5,100,899*PED<disabled>Y<disabled>
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110Aug 22, 2002RXYes5,989,591*PED<disabled>Y<disabled>
Pf Prism Cv
RAPAMUNE
sirolimus
SOLUTION;ORAL021083Sep 15, 1999RXYes5,100,899*PED<disabled>Y<disabled>
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110Feb 23, 2004DISCNNo5,100,899*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: RAPAMUNE

Drugname Dosage Strength RLD Submissiondate
sirolimusTablets0.5 mgRapamune8/25/2010
sirolimusTablets1 mg and 2 mgRapamune12/17/2009
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc